We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

13 hedge funds and large institutions have $241K invested in ABVC BioPharma in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

55% more capital invested

Capital invested by funds: $156K → $241K (+$85.2K)

44% more funds holding

Funds holding: 9 → 13 (+4)

1.32% more ownership

Funds ownership: 1.84% → 3.15% (+1.3%)

Holders
13
Holders Change
+4
Holders Change %
+44.44%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APP
Avantax Planning Partners
Iowa
+$58.6K
2
Citadel Advisors
Citadel Advisors
Florida
+$22.7K
3
VF
Virtu Financial
New York
+$8.89K
4
XT
XTX Topco
Cayman Islands
+$6.14K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.28K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$33

ABVC Hedge Fund Activity: Q4 2024 in Review

13 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2024, worth a combined $241K — up 55% from $156K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ABVC positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Avantax Planning Partners, adding an estimated $58.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $33.

  • 13 institutional investors held ABVC BioPharma (ABVC) as of Q4 2024, up from 9 in Q3 2024.
  • Funds reported $241K of ABVC BioPharma stock for Q4 2024, up 55% quarter-over-quarter.
  • 4 funds opened new ABVC BioPharma positions in Q4 2024 and 0 closed out, a net change of +4 holders.
  • The largest ABVC BioPharma buyer in Q4 2024 was Avantax Planning Partners, an estimated $58.6K added.
  • The largest ABVC BioPharma seller in Q4 2024 was Tower Research Capital (TRC), an estimated $33 sold.

Based on aggregated 13F filings for Q4 2024.